New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:13 EDTAUXL, VVUSVIVUS and Auxilium announces FDA accepted STENDRA's supplemental application
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has accepted a supplemental application that proposes to revise the STENDRA, or avanafil, prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction." The PDUFA date for the supplemental filing is September 20.
News For VVUS;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
16:35 EDTAUXLEndo sees Auxilium transaction immediately accretive
Endo International plc (ENDP)announced it has completed the acquisition of Auxilium Pharmaceuticals (AUXL) in a transaction valued at $2.6B when announced on October 9, 2014. The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27 and the receipt of all required regulatory approvals. Rajiv De Silva, president and CEO of Endo, stated, This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality products to our already robust portfolio and expanding our development pipeline. We are excited to deliver on the promise of this combination by leveraging our resources to enhance the performance of XIAFLEX and optimize TESTOPEL and STENDRA. We continue to expect the transaction to be immediately accretive for shareholders and meaningfully accretive each year moving forward. We believe that Endo is now even better positioned to drive growth across our product portfolio and to capitalize on additional future strategic M&A opportunities to create value for shareholders, customers and employees." Auxilium common stock will cease to be traded on the NASDAQ Global Market following the close of trading on January 29.
07:16 EDTVVUSVIVUS reports EC approval of SPEDRA
Subscribe for More Information
January 27, 2015
09:35 EDTAUXLAuxilium shareholders approve merger with Endo
Subscribe for More Information
January 23, 2015
10:02 EDTVVUSOn the Fly: Analyst Initiation Summary
Subscribe for More Information
09:21 EDTVVUSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Infinera (INFN), up 13.2%... E-Trade (ETFC), up 5.6%... Starbucks (SBUX), up 5%... ResMed (RMD), up 3.2%. ALSO HIGHER: IVUS (VVUS), up 6.2% after being initiated with an Outperform at RBC Capital... Vitae Pharmaceuticals (VTAE), up 12.3% after 3M share Secondary priced at $11.90... lululemon (LULU), up 3.5% after being upgraded to Overweight from Neutral at JPMorgan. DOWN AFTER EARNINGS: Kimberly Clark (KMB), down 4.6%... Bank of New York Mellon (BK), down 2.1%... Altera (ALTR), down 4.4%... Kansas City Southern (KSU), down 3.3%... McDonald's (MCD), down fractionally. ALSO LOWER: LeapFrog (LF), down 32.8% after reporting preliminary third quarter results and withdrawing fiscal 2015 guidance... Molycorp (MCP), down 10.7% after being downgraded to Neutral from Buy at DA Davidson... Dreamworks (DWA), down 12% after announcing that it will cut 500 jobs, reduce films released per year, and seeing a $55M charge for 'The Penguins of Madagascar' and 'Mr. Peabody and Sherman'... Otonomy (OTIC), down 1.8% after secondary increased to 2.55M shares, priced at $29.25.
January 22, 2015
18:28 EDTVVUSOn The Fly: After Hours Movers
Subscribe for More Information
16:15 EDTVVUSVIVUS initiated with an Outperform at RBC Capital
14:03 EDTAUXLAuxilium to host special shareholder meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use